Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
BackgroundAlthough many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated.MethodsWe evaluated the efficacy of glimepiride, metformin, and rosiglitaz...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Diabetes Association
2011-02-01
|
Series: | Diabetes & Metabolism Journal |
Subjects: | |
Online Access: | http://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-35-26.pdf |
id |
doaj-1a5ce222e9564376917ae1df8f5d44f0 |
---|---|
record_format |
Article |
spelling |
doaj-1a5ce222e9564376917ae1df8f5d44f02020-11-24T23:37:53ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872011-02-01351263310.4093/dmj.2011.35.1.262743Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy StudyKun Ho YoonJeong Ah ShinHyuk Sang KwonSeung Hwan LeeKyung Wan MinYu Bae AhnSoon Jib YooKyu Jeung AhnSung Woo ParkKwan Woo LeeYeon Ah SungTae Sun ParkMin Seon KimYong Ki KimMoon Suk NamHye Soon KimIe Byung ParkJong Suk ParkJeong Taek WooHo Young SonBackgroundAlthough many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated.MethodsWe evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels.ResultsHbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P<0.001), from 7.9% to 7.0% in the metformin group (P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group.ConclusionThe efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information.http://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-35-26.pdfDiabetes mellitus, type 2GlimepirideMetforminRosiglitazone |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kun Ho Yoon Jeong Ah Shin Hyuk Sang Kwon Seung Hwan Lee Kyung Wan Min Yu Bae Ahn Soon Jib Yoo Kyu Jeung Ahn Sung Woo Park Kwan Woo Lee Yeon Ah Sung Tae Sun Park Min Seon Kim Yong Ki Kim Moon Suk Nam Hye Soon Kim Ie Byung Park Jong Suk Park Jeong Taek Woo Ho Young Son |
spellingShingle |
Kun Ho Yoon Jeong Ah Shin Hyuk Sang Kwon Seung Hwan Lee Kyung Wan Min Yu Bae Ahn Soon Jib Yoo Kyu Jeung Ahn Sung Woo Park Kwan Woo Lee Yeon Ah Sung Tae Sun Park Min Seon Kim Yong Ki Kim Moon Suk Nam Hye Soon Kim Ie Byung Park Jong Suk Park Jeong Taek Woo Ho Young Son Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study Diabetes & Metabolism Journal Diabetes mellitus, type 2 Glimepiride Metformin Rosiglitazone |
author_facet |
Kun Ho Yoon Jeong Ah Shin Hyuk Sang Kwon Seung Hwan Lee Kyung Wan Min Yu Bae Ahn Soon Jib Yoo Kyu Jeung Ahn Sung Woo Park Kwan Woo Lee Yeon Ah Sung Tae Sun Park Min Seon Kim Yong Ki Kim Moon Suk Nam Hye Soon Kim Ie Byung Park Jong Suk Park Jeong Taek Woo Ho Young Son |
author_sort |
Kun Ho Yoon |
title |
Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study |
title_short |
Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study |
title_full |
Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study |
title_fullStr |
Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study |
title_full_unstemmed |
Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study |
title_sort |
comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study |
publisher |
Korean Diabetes Association |
series |
Diabetes & Metabolism Journal |
issn |
2233-6079 2233-6087 |
publishDate |
2011-02-01 |
description |
BackgroundAlthough many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated.MethodsWe evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels.ResultsHbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P<0.001), from 7.9% to 7.0% in the metformin group (P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group.ConclusionThe efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information. |
topic |
Diabetes mellitus, type 2 Glimepiride Metformin Rosiglitazone |
url |
http://e-dmj.org/Synapse/Data/PDFData/2004DMJ/dmj-35-26.pdf |
work_keys_str_mv |
AT kunhoyoon comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT jeongahshin comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT hyuksangkwon comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT seunghwanlee comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT kyungwanmin comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT yubaeahn comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT soonjibyoo comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT kyujeungahn comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT sungwoopark comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT kwanwoolee comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT yeonahsung comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT taesunpark comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT minseonkim comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT yongkikim comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT moonsuknam comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT hyesoonkim comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT iebyungpark comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT jongsukpark comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT jeongtaekwoo comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy AT hoyoungson comparisonoftheefficacyofglimepiridemetforminandrosiglitazonemonotherapyinkoreandrugnaivetype2diabeticpatientsthepracticalevidenceofantidiabeticmonotherapystudy |
_version_ |
1725518509341933568 |